ClinicalTrials.gg
Not yet recruitingNCT07853742Updated Oct 29, 2026

Omadacycline for Treatment Refractory Mycoplasma Genitalium Urethritis

A Phase 2 interventional study of Omadacycline Oral Tablet in Mycoplasma Genitalium Infection and Urethritis, sponsored by Montefiore Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Montefiore Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Oct 29, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Urethritis from Mycoplasma genitalium is difficult to treat and often does not respond to first line therapy. In this case series study, individuals who have failed first line therapy will receive omadacycline (provided by Paratek Pharmaceuticals) to determine the safety and feasibility of using this agent for this condition.

Read the detailed description

Treatment refractory Mycoplasma genitalium (Mgen) urethritis is an extremely difficult-to-manage clinical entity with inadequate therapeutic options. There are no guidelines for management of patients who fail first-line therapy, with case reports and case series providing limited data into second-line/salvage therapy. In vitro data suggests omadacycline may be active against Mgen and a recent case report provided details on the first refractory case of Mgen cured after omadacycline. In this study individuals with symptomatic Mgen urethritis who have failed first-line therapy (doxycycline followed by moxifloxacin) will receive treatment with omadacycline. The goals of the study are to further explore the efficacy and safety of omadacycline as second-line/salvage therapy in similar cases and to potentially build a foundation for subsequent studies.

02

Conditions studied

  • Mycoplasma Genitalium Infection
  • Urethritis

Keywords

  • Omadacycline
03

In context

Lead sponsor

Montefiore Medical Center is the lead sponsor of 417 studies on the registry; 69 are open to participants now.

Of its 89 completed or terminated interventional studies of FDA-regulated products, 77 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Symptomatic urethritis (dysuria, urethral discomfort, pain, or discharge) from Mgen (exclusion of Chlamydia trachomatis, Neisseria gonorrhea, and Trichomonas vaginalis by NAAT)
  • Treatment- infection, defined as persistent symptoms and Mgen NAAT positivity ≥21 days after completion of initial treatment. Initial treatment based on Centers for Disease Control and Prevention (CDC) guidelines: doxycycline (100 mg twice daily for seven days) followed by moxifloxacin (400 mg once daily for seven days)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Allergy or severe intolerance to omadacycline or any of its components
  • Baseline (ALT) or aspartate aminotransferase (AST) ≥ 3 × (ULN), as determined on screening visit liver function tests (LFTs).
  • Baseline total > 1.5 × ULN
  • Suspected or confirmed clinical evidence of end-stage liver disease (e.g., ascites, hepatic encephalopathy)
  • Patient reported condomless sexual activity occurring between completion of Mgen treatment and subsequent positive NAAT test
  • Inability of the patient to reasonably expect to avoid condomless sex during the study's 35-day follow-up period between starting study omadacycline and date of follow up test
  • Based on investigator judgement, significant uncertainty about adherence to prior first-line treatments
  • Based on investigator judgement, significant uncertainty about the subject's interest in or ability to adhere to omadacycline
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Prospective Cohort

    Patients will receive 28 tablets of 150 mg omadacycline, taken as 300 mg daily for 14 days.

    Drug: Omadacycline Oral Tablet

Interventions

  • DrugOmadacyclineStudies of OmadacyclineOmadacycline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 28 tablets of 150 milligrams (mg) of omadacycline, taken as 300 mg daily for 14 days.

    Also known as: Nuzyra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Microbiological Cure of Mycoplasma genitalium

    Microbiological cure is defined as having a negative nucleic acid amplification test (NAAT) for Mycoplasma genitalium at the Day 35 test of cure visit. The NAAT is performed on a self-collected urine specimen or a urogenital swab. Participants with a positive NAAT result are classified as not cured (continue to have an active infection). Participants who do not attend the Day 35 (+/- 7 days) visit or from whom no evaluable specimen is obtained are classified as not cured. The denominator is all enrolled participants who received at least one dose of omadacycline. If any participants included in the study are unable to complete the full 14 days of the medication for any reason they will be evaluated based on their outcome from their Day 35 NAAT.

    Time frame: Day 35 (+/- 7 days), 21 days after completion of the 14-day omadacycline course

Secondary outcomes

  1. Safety and Tolerability of omadacycline

    Safety and tolerability of omadacycline will be assessed in tandem using the 20-item PHArmacotherapeutical Symptom Evaluation (PHASE-20) rating scale. The scale consists of 19 specific potential drug-related symptoms plus 1 open-ended category and evaluates whether symptoms experienced during the follow-up period may be related to the medication. For each item, participants will be asked to "tick the box" that best describes symptoms they experienced over the last 2 weeks and circle the appropriate term(s) when a multi-symptom item is presented if all symptoms don't apply. Each of the 20 items is rated on a 4-point ordinal scale: 0 (No problem), 1 (Minor problem), 2 (Moderate problem), and 3 (Severe problem), yielding an overall possible score of 0-60 with higher scores being indicative of a greater burden of possible medication-related symptoms. The scale is administered by telephone at Day 14 and in person at Day 35. Scores are reported separately at each time point.

    Time frame: At 14 (+/- 5 days) and 35 days (+/- 7 days) after study drug administration

  2. Number of Participants with One or More Treatment-Emergent Adverse Events

    A treatment-emergent adverse event (TEAE) is defined as any adverse event with onset on or after the first dose of omadacycline. Events are identified by the investigator team assessment during the Day 14 (+/- 5 days) telephone contact and the Day 35 (+/- 7 days) clinic visit, and by participant-initiated reporting at any time during the study period. Each event is characterized by severity and by investigator-assessed relationship to omadacycline. Participants reporting more than one event are counted once.

    Time frame: Day 1 (first dose administration) through Day 35 (+/- 7 days)

07

Study locations

1 site
  • The Oval Center at Montefiore Medical Center
    The Bronx, New York 10467, United States
08

References and documents

Publications

  • Waites KB, Crabb DM, Atkinson TP, Geisler WM, Xiao L. Omadacycline Is Highly Active In Vitro against Mycoplasma genitalium. Microbiol Spectr. 2022 Dec 21;10(6):e0365422. doi: 10.1128/spectrum.03654-22. Epub 2022 Oct 31. PubMed 36314935 ↗
  • Patel NM. Case Report: First In-Human Report of Cure of Refractory Mycoplasma genitalium Infection With Omadacycline. Open Forum Infect Dis. 2026 Mar 30;13(Suppl 2):S1398-S1401. doi: 10.1093/ofid/ofag030. eCollection 2026 Apr. PubMed 41918853 ↗
  • Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1. PubMed 34292926 ↗
  • Hedstrom M, Carlsson M, Ekman A, Gillespie U, Mork C, Asberg KH. Development of the PHASE-Proxy scale for rating drug-related signs and symptoms in severe cognitive impairment. Aging Ment Health. 2018 Jan;22(1):53-60. doi: 10.1080/13607863.2016.1232364. Epub 2016 Sep 22. PubMed 27657536 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jul 2027, 6 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Oct 2026 → Jan 2027, primary completion Apr 2027 → Jul 2027 and completion Apr 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 2, 2026
StartEst.
Jan 2027was Oct 2026
Primary completionEst.
Jul 2027was Apr 2027
CompletionEst.
Jul 2027was Apr 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jan 2027
Oct 29, 2026
Primary completion
Apr 2027→Jul 2027
Oct 29, 2026
Study completion
Apr 2027→Jul 2027
Oct 29, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 29, 2026
    Start date Oct 2026→Jan 2027
    Primary completion Apr 2027→Jul 2027
    Study completion Apr 2027→Jul 2027
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07853742
Collaborators
Paratek Pharmaceuticals Inc
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Eric A Meyerowitz, MD
Contact
emeyerowit@montefiore.org
718-882-5482
Caroline Mullis, MD, MS
Contact
cmullis@montefiore.org
718-882-5482
Eric A Meyerowitz, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omadacycline

Start the discussion